The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Open accessAbstract
Atherosclerosis is a multifactorial highly-complex disease with numerous etiologies that work synergistically to promote lesion development. The ability to develop preventive and ameliorative treatments will depend on animal models that mimic the human subject metabolically and pathophysiologically and will develop lesions comparable to those in humans. The mouse is the most useful, economic, and valid model for studying atherosclerosis and exploring effective therapeutic approaches. Among the most widely used mouse models for atherosclerosis are apolipoprotein E–deficient (ApoE −/− ) and LDL receptor–deficient (LDLr −/− ) mice. An up-and-coming model is the ApoE*3Leiden (E3L) transgenic mouse. Here, we review studies that have explored how and to what extent these mice respond to compounds directed at treatment of the risk factors hypercholesterolemia, hypertriglyceridemia, hypertension, and inflammation. An important outcome of this survey is that the different models used may differ markedly from one another in their response to a specific experimental manipulation. The choice of a model is therefore of critical importance and should take into account the risk factor to be studied and the working spectrum of the compounds tested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The immune response in atherosclerosis: a double-edged sword
Hansson, G. K., & Libby, P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1882 · Cited by 2,182
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.
Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L., & Ross, R. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.1.133 · Cited by 1,693
Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E–deficient mice
Daugherty, A., Manning, M. W., & Cassis, L. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7818 · Cited by 1,368
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170
Oliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
Liver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978
Synthetic LXR ligand inhibits the development of atherosclerosis in mice
Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R., Laffitte, B. A., Chen, M., Noh, G., Goodman, J., Hagger, G. N., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112059299 · Cited by 947
Li, A. C., Brown, K. K., Silvestre, M. J., Willson, T. M., Palinski, W., & Glass, C. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10370 · Cited by 833
Cited by
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Cytokines and atherosclerosis: a comprehensive review of studies in mice
Kleemann, R., Zadelaar, S., & Kooistra, T. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn120 · Cited by 606
Self-citationPathological effects of ionizing radiation: endothelial activation and dysfunction
Baselet, B., Sonveaux, P., Baatout, S., & Aerts, A. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2956-z · Cited by 552
Animal models of atherosclerosis
Emini Veseli, B., Perrotta, P., De Meyer, G. R. A., Roth, L., Van der Donckt, C., Martinet, W., & De Meyer, G. R. Y. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.010 · Cited by 548
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I., & Tao, W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 518
Translating molecular discoveries into new therapies for atherosclerosis
Rader, D. J., & Daugherty, A. (2008) · Nature · doi:10.1038/nature06796 · Cited by 515
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
Animal Models of Cardiovascular Diseases
Zaragoza, C., Gomez-Guerrero, C., Martin-Ventura, J. L., Blanco-Colio, L., Lavin, B., Mallavia, B., Tarin, C., Mas, S., Ortiz, A., & Egido, J. (2011) · BioMed Research International · doi:10.1155/2011/497841 · Cited by 402
Kleemann, R., Verschuren, L., Morrison, M., Zadelaar, S., van Erk, M. J., Wielinga, P. Y., & Kooistra, T. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.023 · Cited by 401
Self-citationden Hartigh, L. (2019) · Nutrients · doi:10.3390/nu11020370 · Cited by 371
Meta-Analysis of Leukocyte Diversity in Atherosclerotic Mouse Aortas
Zernecke, A., Winkels, H., Cochain, C., Williams, J. W., Wolf, D., Soehnlein, O., Robbins, C. S., Monaco, C., Park, I., McNamara, C. A., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.316903 · Cited by 378
The roles of senescence and telomere shortening in cardiovascular disease
Fyhrquist, F., Saijonmaa, O., & Strandberg, T. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.30 · Cited by 372
Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease
Maguire, E. M., Pearce, S. W. A., & Xiao, Q. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2018.08.002 · Cited by 366
Wei, X., Ying, M., Dehaini, D., Su, Y., Kroll, A. V., Zhou, J., Gao, W., Fang, R. H., Chien, S., & Zhang, L. (2018) · ACS Nano · doi:10.1021/acsnano.7b07720 · Cited by 329
Mechanisms of Action of trans Fatty Acids
Oteng, A.-B., & Kersten, S. (2020) · Advances in Nutrition · doi:10.1093/advances/nmz125 · Cited by 308
Silencing of Lipid Metabolism Genes through IRE1α-Mediated mRNA Decay Lowers Plasma Lipids in Mice
So, J.-S., Hur, K. Y., Tarrio, M., Ruda, V., Frank-Kamenetsky, M., Fitzgerald, K., Koteliansky, V., Lichtman, A. H., Iwawaki, T., Glimcher, L. H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.004 · Cited by 280
Wasan, K. M., Brocks, D. R., Lee, S. D., Sachs-Barrable, K., & Thornton, S. J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2353 · Cited by 269
Ye, D., Li, F. Y. L., Lam, K. S. L., Li, H., Jia, W., Wang, Y., Man, K., Lo, C. M., Li, X., & Xu, A. (2012) · Gut · doi:10.1136/gutjnl-2011-300269 · Cited by 206
“ApoE-deficient mice (ApoE / ) fed with Western-style atherogenic diet have been widely used as a rodent model for atherosclerosis.(16) A number of studies have shown that ApoEnull mice may develop the full-spectrum of liver pathology that characterises human NASH in an appropriate metabolic context similar to obesity.”
MethodKühnast, S., van der Hoorn, J. W. A., Pieterman, E. J., van den Hoek, A. M., Sasiela, W. J., Gusarova, V., Peyman, A., Schäfer, H.-L., Schwahn, U., Jukema, J. W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m051326 · Cited by 204
Self-citationAllen, R. M., Marquart, T. J., Albert, C. J., Suchy, F. J., Wang, D. Q. ‐., Ananthanarayanan, M., Ford, D. A., & Baldán, Á. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201228 · Cited by 159
Large animal models of cardiovascular disease
Tsang, H. G., Rashdan, N. A., Whitelaw, C. B. A., Corcoran, B. M., Summers, K. M., & MacRae, V. E. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3173 · Cited by 154
Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis
Kojima, Y., Downing, K., Kundu, R., Miller, C., Dewey, F., Lancero, H., Raaz, U., Perisic, L., Hedin, U., Schadt, E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70391 · Cited by 148
Time-Resolved and Tissue-Specific Systems Analysis of the Pathogenesis of Insulin Resistance
Kleemann, R., van Erk, M., Verschuren, L., van den Hoek, A. M., Koek, M., Wielinga, P. Y., Jie, A., Pellis, L., Bobeldijk-Pastorova, I., Kelder, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008817 · Cited by 146
“In the present study we used E3L mice, which exhibit a humanized lipoprotein metabolism [11,37], and treated these mice with a HF diet for 12 weeks.”
MethodSelf-citationSkagen, K., Trøseid, M., Ueland, T., Holm, S., Abbas, A., Gregersen, I., Kummen, M., Bjerkeli, V., Reier-Nilsen, F., Russell, D., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.033 · Cited by 139
Jahagirdar, R., Zhang, H., Azhar, S., Tobin, J., Attwell, S., Yu, R., Wu, J., McLure, K. G., Hansen, H. C., Wagner, G. S., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.008 · Cited by 134
Salic, K., Morrison, M. C., Verschuren, L., Wielinga, P. Y., Wu, L., Kleemann, R., Gjorstrup, P., & Kooistra, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.001 · Cited by 105
“The anti-atherosclerotic activities of statins in ApoE*3Leiden transgenic mice are strongly related to their (V)LDL cholesterollowering effects[10], and high statin doses are needed to substantially quench inflammation [20, 23, 24].”
BackgroundInfluentialSelf-citationLiu, M., Yu, Y., Jiang, H., Zhang, L., Zhang, P.-P., Yu, P., Jia, J.-G., Chen, R.-Z., Zou, Y.-Z., & Ge, J.-B. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.8 · Cited by 69
Marais, A. D., Solomon, G. A. E., & Blom, D. J. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.870526 · Cited by 70
Skajaa, T., Cormode, D. P., Jarzyna, P. A., Delshad, A., Blachford, C., Barazza, A., Fisher, E. A., Gordon, R. E., Fayad, Z. A., & Mulder, W. J. M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.08.078 · Cited by 69
Petriello, M. C., Brandon, J. A., Hoffman, J., Wang, C., Tripathi, H., Abdel-Latif, A., Ye, X., Li, X., Yang, L., Lee, E., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfx275 · Cited by 67
Pouwer, M. G., Pieterman, E. J., Worms, N., Keijzer, N., Jukema, J. W., Gromada, J., Gusarova, V., & Princen, H. M. G. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000419 · Cited by 66
Self-citationChen, Y., Ku, H., Zhao, L., Wheeler, D. C., Li, L.-C., Li, Q., Varghese, Z., Moorhead, J. F., Powis, S. H., Huang, A., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301301 · Cited by 61
Engel, D. F., de Oliveira, J., Lopes, J. B., Santos, D. B., Moreira, E. L. G., Farina, M., Rodrigues, A. L. S., de Souza Brocardo, P., & de Bem, A. F. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.029 · Cited by 44
In Vitro Modeling of Atherosclerosis Using iPSC‐Derived Blood Vessel Organoids
Kong, D., Ryu, J., Shin, N., Lee, S., Kim, N. G., Kim, H., Kim, M., Choi, J., Kim, D., & Kang, K. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202400919 · Cited by 36
Genomics and Cardiovascular Drug Development
Plump, A. S., & Lum, P. Y. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.050 · Cited by 31
The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis
Sallam, T., Ito, A., Rong, X., Kim, J., van Stijn, C., Chamberlain, B. T., Jung, M. E., Chao, L. C., Jones, M., Gilliland, T., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m047548 · Cited by 30
Calkin, A. C., Lee, S. D., Kim, J., Van Stijn, C. M. W., Wu, X.-H., Lusis, A. J., Hong, C., Tangirala, R. I., & Tontonoz, P. (2014) · Circulation Research · doi:10.1161/circresaha.115.304440 · Cited by 27
Inhibition of Angiotensin II‐Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice
Choi, S. Y., Park, J. S., Roh, M. S., Kim, C., Kim, M. H., & Serebruany, V. (2017) · Lipids · doi:10.1007/s11745-017-4246-1 · Cited by 15
Metadata
- Authors
- Zadelaar, S., Kleemann, R., Verschuren, L., de Vries-Van der Weij, J., van der Hoorn, J., Princen, H. M., & Kooistra, T.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2007-08
- Volume
- 27
- Issue
- 8
- Pages
- 1706-1721
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2105924650
- Cited by
- 527
- References
- 139
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.